Floatz logo

LEUPROLIDE

Hormone Therapy

National Taiwan University Hospitalprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hormone Therapy cohort.

Asset / SponsorPhaseRating
Letrozole
National Taiwan University Hospital
Phase 2CCC
FULVESTRANT
National Taiwan University Hospital
Phase 2CCC
Zoladex
National Taiwan University Hospital
Phase 2CCC

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →